CEL-SCI's Multikine Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to Be in the Treatment Group for Surgery and Radiation
CEL-SCI to Present New Data for Multikine Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress
The UK's MHRA Grants CEL-SCI's Multikine A Product Specific Waiver For The Treatment Of Head And Neck Cancer In A Pediatric Population Of People Up To 18 Years Of Age
CEL-SCI Q3 2024 Adj EPS $(0.14) Misses $(0.11) Estimate
Express News | CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results
CEL-SCI 3Q Loss/Shr 14c >CVM